CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 15 enrolled
Drug / intervention
metformin HCldrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03398824
NCT03398824Phase 2Completed
CompareCT.gov

Pilot Study of Metformin for Patients With Fanconi Anemia

Boston Children's Hospital·interventional·Posted Jan 16, 2018·Updated Nov 29, 2022

In Brief

A Phase 2 clinical trial evaluating metformin HCl for Fanconi Anemia. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This is a single institution, open-label, single arm pilot study of Metformin in patients with Fanconi Anemia (FA) and cytopenias with the primary endpoint of hematologic response. This study will also assess safety, tolerability, and the biologic effects of Metformin in patients with FA.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsFanconi Anemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJan 16, 2018
Enrollment StartMar 29, 2018
Primary CompletionOct 9, 2020
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 8.5 years ago

Interventions

metformin HCldrug

Receive metformin HCl